Kirkland Dickey
Primary Care · Pine Hall, NCNPI 1114589884
Payments from drug & device makers
Across 581 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- Novo Nordisk$1K
- Lilly USA, LLC$992
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$859
- Pfizer$816
- plus $3K from 25 others
What the payments were for
- Food & beverage$10,555100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $2,033 |
| AbbVie | 109 | $1,555 |
| Novo Nordisk | 74 | $1,087 |
| Lilly USA, LLC | 62 | $992 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $859 |
| Pfizer | 44 | $816 |
| GSK | 41 | $627 |
| Boehringer Ingelheim | 23 | $392 |
| Bayer | 11 | $279 |
| Biohaven Pharmaceuticals, Inc. | 7 | $254 |
| Sanofi-aventis U.S. LLC | 11 | $198 |
| Amarin Pharma, Inc. | 11 | $188 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $133 |
| Amgen | 9 | $123 |
| Vanda Pharmaceuticals Inc. | 6 | $122 |
| Lundbeck LLC | 5 | $107 |
| E.r. Squibb & Sons, L.L.C. | 3 | $101 |
| Viatris Specialty LLC | 5 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Paratek Pharmaceuticals, Inc. | 4 | $62 |
| Esperion Therapeutics, Inc. | 3 | $55 |
| Exact Sciences | 2 | $42 |
| Eisai Inc. | 2 | $30 |
| Johnson & Johnson | 1 | $21 |
| Mylan Specialty L.p. | 1 | $21 |
| Alkermes, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Theratechnologies Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,561 in reported general payments places this provider in the 95th percentile of 236 primary care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 122 | $204,039 |
| FarxigaDapagliflozin Propanediol | 241 | $195,919 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 199 | $146,969 |
| MounjaroTirzepatide | 115 | $131,986 |
| JardianceEmpagliflozin | 166 | $123,916 |
| VraylarCariprazine Hcl | 81 | $121,983 |
| OzempicSemaglutide | 113 | $113,276 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $102,758 |
| EliquisApixaban | 138 | $96,915 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $58,475 |
| RybelsusSemaglutide | 36 | $54,038 |
| Emgality PenGalcanezumab-Gnlm | 40 | $35,932 |
| XareltoRivaroxaban | 38 | $31,216 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $29,329 |
| LinzessLinaclotide | 47 | $28,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,033 | $354,178471 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $859 | $204,039122 claims |
| Novo NordiskOzempic, Rybelsus | $1,087 | $167,314149 claims |
| Lilly USA, LLCMounjaro, Trulicity | $992 | $158,721141 claims |
| AbbVieVraylar, Linzess | $1,555 | $150,194128 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr | $392 | $140,833207 claims |
| GSKTrelegy Ellipta | $627 | $102,758123 claims |
| PfizerEliquis | $816 | $96,915138 claims |
| Johnson & JohnsonXarelto | $21 | $31,21638 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $82 | $19,85718 claims |
| BayerKerendia | $279 | $16,13820 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $198 | $15,64212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 236 primary care providers in North Carolina.
Other primary care in Pine Hall
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
- Mark HollingsworthWilmington$7K
- Crystal GoinsFayetteville$7K
- Kenzie Midgette DavisGreenville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.